Addition of the antipsychotic lumateperone (Caplyta) to an existing antidepressant improved symptoms of depression in a randomized, double-blind phase III trial. Among 484 patients with major ...
Company remains sharply focused on its ongoing global development program for crofelemer for rare IF diseases Near-term ...
Dermocosmetics as adjunctive therapy improved skin sensitivity and reduced acne severity, especially in retinoid users, over a 12-week period. Quality of life scores increased post-treatment, with the ...
Please provide your email address to receive an email when new articles are posted on . Caplyta had been previously approved by FDA for bipolar I and II depression and schizophrenia. Approval was ...
Please provide your email address to receive an email when new articles are posted on . Severe disability and all-cause mortality were lower at 6 months among patients given infliximab. No ...
LONDON--(BUSINESS WIRE)-- LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, today announced that 24-month data on generalized tonic-clonic (GTC) seizures in people with ...
The use of 42 mg lumateperone combined with antidepressant therapy was linked to significantly reduced severity of depression and anxiety, as well as greater response and remission rates, and was ...
Statistically significantly effects were observed as early as week 1 and maintained throughout the study. Treatment with lumateperone significantly reduced depressive symptoms in patients with major ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results